Article

The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence

2021-01-29

Abstract excerpt

<h4>Background</h4> BNT162b2 vaccines showed high efficacy against COVID-19 in a randomised controlled phase-III trial. A vaccine effectiveness evaluation in real life settings is urgently needed, especially given the global disease surge. Hence, we assessed the short-term effectiveness of the first dose of BNT162b2-vaccine against SARS-CoV-2 infection. Given the BNT162b2 Phase-III results, we hypothesized that th...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 67600274-1fc7-597d-bf75-64551b538e78
DOI: 10.1101/2021.01.27.21250612

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidenceDOI 10.1101/2021.01.27.21250612Read

The Effectiveness of the First Dose of BNT162b2 Vaccine in Reducing SARS-CoV-2 Infection: Real-World EvidenceSemantic proximity Read

Relative Effectiveness of Four Doses Compared to Three Dose of the BNT162b2 Vaccine in IsraelSemantic proximity Read

BNT162b2 mRNA Vaccine Effectiveness Given Confirmed Exposure; Analysis of Household Members of COVID-19 PatientsSemantic proximity Read

Effectiveness of the BNT162b vaccine fourth dose in reducing SARS-CoV-2 infection among healthcare workers in Israel, a multi-center cohort studySemantic proximity Read

Waning of SARS-CoV-2 vaccine-induced immunity: A systematic review and secondary data analysisSemantic proximity Read

Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in QatarSemantic proximity Read

BNT162B2 mRNA Covid-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in the Medium - to Long-Term: A Retrospective Cohort StudySemantic proximity Read

Short Term Reduction in the Odds of Testing Positive for SARS-CoV-2; a Comparison Between Two Doses and Three doses of the BNT162b2 VaccineSemantic proximity Read

Effectiveness of BNT162b2 mRNA COVID-19 Vaccine Against SARS-CoV-2 Variant Beta (B.1.351) Among Persons Identified Through Contact Tracing in IsraelSemantic proximity Read

BNT162b2 vaccine booster dose protection: A nationwide study from IsraelSemantic proximity Read

Effectiveness of the WHO-authorized Covid-19 Vaccines: a Rapid Review of Global Reports till June 30, 2021Semantic proximity Read

Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron VariantSemantic proximity Read